CSE CALI  |  Last $0.09  |  Change 0.00 OTC FNNZF  |  Last $0.07  |  Change 0.00

Our mission is to combine extensive investment expertise, and industry experience in providing growth capital to rapidly emerging private companies operating in the licensed U.S. cannabis industry with a focus on California.

The Company’s vision is to be the capital partner of choice for rapidly emerging companies focused on the licensed U.S. cannabis industry.

Why Are We Focused on Licensed Cannabis?

Licensed cannabis is becoming legalized rapidly on a global scale and while FinCanna is focusing on this sector, it is confident that its investors and portfolio companies will benefit from this focus.

According to Arcview Market Research and partner BDS Analytics, worldwide spending on legal cannabis is expected to hit $57 billion by 2027. North America will continue to be the leader in legal cannabis buyers, as the $9.2 billion spent in 2017 is expected to grow to $47.3 billion by 2027. [2]

Research at the University of Georgia has also found a link between medical cannabis and the decrease in opioid prescriptions in the states that permit dispensaries. The findings show from 2010 to 2015,  prescriptions filled for all opioids decreased by 2.11 million. [3] As more cures and treatments are discovered and proven, the role of medical cannabis is sure to expand.

The U.S. Cannabis Industry and California

  • California is the largest cannabis market in North America, representing ~$2.75 billion in sales[6];

  • The North America legal cannabis market grew by 37% in 2017, with a total worth of $9.5 billion. The U.S. accounted for $8.5 billion, followed by Canada with $0.6 billion[4]

  • California not only has the largest state economy in the U.S., it is also fifth largest economy in the world. With cannabis sales projected to total US$7.7 billion by 2022, [5] California is recognized as a global leader of the cannabis market.

  • The state licensed cannabis market in the U.S. is expected to reach over $24 billion by 2025, indicating an overall CAGR of 16%[7].

[1]Reuters, 2017. https://www.reuters.com/article/us-israel-cannabis/israel-looks-to-leverage-tech-in-50-billion-medical-marijuana-market-idUSKBN16U1PZ

[2]Forbes, 2018. https://www.forbes.com/sites/thomaspellechia/2018/03/01/double-digit-billions-puts-north-america-in-the-worldwide-cannabis-market-lead/#40c1ce426510

[3]  University of Georgia, 2018 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2676999?redirect=true
[4] Forbes, 2018. 
[5] Cannabis Business Plans, 2018. https://cannabusinessplans.com/california-cannabis-market/

[6] Forbes, 2018. https://www.forbes.com/sites/andrewdepietro/2018/05/04/how-much-money-states-make-cannabis-sales

[7] Visual Capitalist, 2018. https://www.visualcapitalist.com/green-rush-cannabis-legalization-will-impact-california/

Subscribe for Updates